Best of the Week
Most Popular
1. 2019 From A Fourth Turning Perspective - James_Quinn
2.Beware the Young Stocks Bear Market! - Zeal_LLC
3.Safe Havens are Surging. What this Means for Stocks 2019 - Troy_Bombardia
4.Most Popular Financial Markets Analysis of 2018 - Trump and BrExit Chaos Dominate - Nadeem_Walayat
5.January 2019 Financial Markets Analysis and Forecasts - Nadeem_Walayat
6.Silver Price Trend Analysis 2019 - Nadeem_Walayat
7.Why 90% of Traders Lose - Nadeem_Walayat
8.What to do With Your Money in a Stocks Bear Market - Stephen_McBride
9.Stock Market What to Expect in the First 3~5 Months of 2019 - Chris_Vermeulen
10.China, Global Economy has Tipped over: The Surging Dollar and the Rallying Yen - FXCOT
Last 7 days
Stock Market VIX Volaility Analysis - 19th Mar 19
FREE Access to Stock and Finanacial Markets Trading Analysis Worth $1229! - 19th Mar 19
US Stock Markets Price Anomaly Setup Continues - 19th Mar 19
Gold Price Confirmation of the Warning - 18th Mar 19
Split Stock Market Warning - 18th Mar 19
Stock Market Trend Analysis 2019 - Video - 18th Mar 19
Best Precious Metals Investment and Trades for 2019 - 18th Mar 19
Hurdles for Gold Stocks - 18th Mar 19
Pento: Coming QE & Low Rates Will Be ‘Rocket Fuel for Gold’ - 18th Mar 19
"This is for Tommy Robinson" Shouts Knife Wielding White Supremacist Terrorist in London - 18th Mar 19
This Is How You Create the Biggest Credit Bubble in History - 17th Mar 19
Crude Oil Bulls - For Whom the Bell Tolls - 17th Mar 19
Gold Mining Stocks Fundamentals - 17th Mar 19
Why Buy a Land Rover - Range Rover vs Huge Tree Branch Falling on its Roof - 17th Mar 19
UKIP Urged to Change Name to BNP 2.0 So BrExit Party Can Fight a 2nd EU Referendum - 17th Mar 19
Tommy Robinson Looks Set to Become New UKIP Leader - 16th Mar 19
Gold Final Warning: Here Are the Stunning Implications of Plunging Gold Price - 16th Mar 19
Towards the End of a Stocks Bull Market, Short term Timing Becomes Difficult - 16th Mar 19
UKIP Brexit Facebook Groups Reveling in the New Zealand Terror Attacks Blaming Muslim Victims - 16th Mar 19
Gold – US Dollar vs US Dollar Index - 16th Mar 19
Islamophobic Hate Preachers Tommy Robinson and Katie Hopkins have Killed UKIP and Brexit - 16th Mar 19
Countdown to The Precious Metals Gold and Silver Breakout Rally - 15th Mar 19
Shale Oil Splutters: Brent on Track for $70 Target $100 in 2020 - 15th Mar 19
Setting up a Business Just Got Easier - 15th Mar 19
Stock Market Elliott Wave Analysis Trend Forercast - Video - 15th Mar 19
Gold Warning - Here Are the Stunning Implications of Plunging Gold Price - Part 1 - 15th Mar 19
UK Weather SHOCK - Trees Dropping Branches onto Cars in Stormy Winds - Sheffield - 15th Mar 19
Best Time to Trade Forex - 15th Mar 19
Why the Green New Deal Will Send Uranium Price Through the Roof - 14th Mar 19
S&P 500's New Medium-Term High, but Will Stock Market Uptrend Continue? - 14th Mar 19
US Conservatism - 14th Mar 19
Gold in the Age of High-speed Electronic Trading - 14th Mar 19
Britain's Demographic Time Bomb Has Gone Off! - 14th Mar 19
Why Walmart Will Crush Amazon - 14th Mar 19
2019 Economic Predictions - 14th Mar 19
Tax Avoidance Bills Sent to Thousands of Workers - 14th Mar 19
The Exponential Stocks Bull Market Explained - Video - 13th Mar 19
TSP Recession Indicator - Criss-Cross, Flip-Flop and Remembering 1966 - 13th Mar 19
Stock Investors Beware The Signs Of Recession / Deflation - 13th Mar 19
Is the Stock Market Still in a Bear Market? - 13th Mar 19
Stock Market Trend Analysis 2019 - 13th Mar 19
Gold Up-to-Date' COT Report: A Maddening Déjà Vu - 12th Mar 19
Save Fintech? Ban Short Selling. It's Not That Simple - 12th Mar 19
Palladium Blowup Could Expose Scam of Gold & Silver Futures - 12th Mar 19
Next Recession: Concentrating Future Losses & Bringing Them Forward In Time As Profits - 12th Mar 19
The Shift of the Philippine Peso Regime - 12th Mar 19
Theresa May BrExit Back Stab Deal Counting Down to Resignation, Tory Leadership Election - 12th Mar 19
Phase 1 of Stock Market Correction - 11th Mar 19
Long Awaited Stock Market Pullback has Finally Arrived - 11th Mar 19
US Presidential Cycle and the Stock Market - Video - 11th Mar 19
Stock Market Elliott Wave Analysis Trend Forercast - 11th Mar 19
Chinese Economic Data Shakes the Global Stock Markets - 11th Mar 19
The Fed Is Playing a Dangerous Game - 11th Mar 19
The Stock Market Has Called the Fed’s Bluff, What’s Next? - 11th Mar 19
Turkey Holiday Bazaar Extreme Jewelry Price Haggling - Fethiye Market - 11th Mar 19

Market Oracle FREE Newsletter

Stock and Finanacial Markets Trading Analysis Worth

Is TamiFlu a Scam?

Politics / Global Pandemic Dec 08, 2009 - 11:47 AM GMT

By: Nadeem_Walayat

Politics

The NHS has spent more than £500 million on TamiFlu on the premise that it will prevent the transmission of flu and hospitalisation of Swine Flu patients. To help disburse millions of dosages costing £70 each, the NHS introduced a National Flu helpline during mid 2009 and an online service which has allowed millions of patients to obtain Tami-flu prescription authorisation after just a few mouse clicks.


However Channel 4 News is now reporting that the key paper on which the effectiveness of TamiFlu makers Roche claims are based are being questioned by scientists as the drug maker is apparently refusing to make the vital data available to scientists for peer review.

Channel 4 reports further that other studies on the efftiveness of Swine flu do not stand up to clinical research - New doubts over Tamiflu

Governments around the world stockpiled supplies. In the UK alone the estimated bill for Tamiflu is approaching half a billion pounds.

Tonight Channel 4 News can reveal that serious scientific questions are being raised over the evidence base for Tamiflu.

Scientists we have spoken to say they have been unable to judge and properly test some of the claims made about the antiviral by its makers, Roche.

Claims about the drug's effectiveness in reducing hospitalisations have been a key factor in decisions by governments around the world to stockpile Tamiflu (oseltamivir). Manufacturer Roche estimates that sales of Tamiflu this year will reach £1.6bn.

Tamiflu's benefits are well-publicised. Advocates say it reduces the chance of flu being transmitted in the first place, and that once someone has become infected it shortens the duration of the illness. Today's review confirms these findings.

But the drug is also credited with reducing complications and hospitalisations in those who develop full-blown flu. In a recent interview Roche Pharmaceuticals CEO William Burns said: "What Tamiflu can do is actually reduce hospitalisations by more than 60 per cent, which is really important if we are in the midst of a major pandemic."

This is the claim now under scrutiny. The investigation by Channel 4 News and the British Medical Journal (BMJ) has discovered that an independent team of scientists has been unable to verify the scientific evidence-base to support it.

The review, commissioned in July by the NHS and published today at BMJ.com, was conducted by the Cochrane Collaboration - a worldwide group of scientists and researchers that reviews medical research. They are internationally recognised for their work.

Speaking on Chanenl 4 News, Dr Tom Jefferson, one of the Cochrane reviewers said: "This is not just any drug, this is a public health drug which is recommended by governments...  and the World Health Organisation - and has been recommended for some years."

Much of the Cochrane team's work has looked at the leading piece of clinical research supporting claims that Tamiflu reduces hospitalisations. This research was authored by swiss scientist Professor Laurent Kaiser.

His research, based on 10 clinical trials set up by Roche found that Tamiflu reduced by 59 per cent the number of people with flu who ended up in hospital. Roche have repeatedly referred to Professor Kaiser's paper when talking about Tamiflu's ability to reduce hospitalisations.

The study released today acknowledges that Tamiflu has a modest effect in reducing symptoms and duration of illness in otherwise healthy adults by about one day, but says there is insufficient published data to independently confirm  its effects on reducing complications leading to hospitalisations .

When the Cochrane reviewers approached Professor Kaiser for the original data in order to verify his conclusions, he said he didn't have it and referred them to  Roche. However, following detailed communication with the company, Roche did not supply the Cochrane team with the complete data they had requested and they were unable to verify the paper's findings.

Because they were unable to independently verify this data, the Cochrane review disregarded Kaiser’s paper from their analysis of the scientific evidence base supporting Tamiflu’s effectiveness in reducing complications.  This removes a key plank of evidence supporting a claim repeatedly made by Roche and governments like ours.

And without this study, the reviewers came to a stark conclusion. Dr Jefferson told Channel 4 News: "We didn't find any convincing evidence that Tamiflu affects complications such as as hospitalisations and chest infections."

Source:

By Nadeem Walayat
http://www.marketoracle.co.uk

Copyright © 2005-09 Marketoracle.co.uk (Market Oracle Ltd). All rights reserved.

Nadeem Walayat has over 20 years experience of trading derivatives, portfolio management and analysing the financial markets, including one of few who both anticipated and Beat the 1987 Crash. Nadeem's forward looking analysis specialises on the housing market and interest rates. Nadeem is the Editor of The Market Oracle, a FREE Daily Financial Markets Analysis & Forecasting online publication. We present in-depth analysis from over 400 experienced analysts on a range of views of the probable direction of the financial markets. Thus enabling our readers to arrive at an informed opinion on future market direction. http://www.marketoracle.co.uk

Disclaimer: The above is a matter of opinion provided for general information purposes only and is not intended as investment advice. Information and analysis above are derived from sources and utilising methods believed to be reliable, but we cannot accept responsibility for any trading losses you may incur as a result of this analysis. Individuals should consult with their personal financial advisors before engaging in any trading activities.

Nadeem Walayat Archive

© 2005-2019 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in

6 Critical Money Making Rules